Trial Profile
Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Chronic heart failure; Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms Iron Turtle
- 05 Dec 2017 Status changed from recruiting to completed.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.
- 15 Feb 2017 New trial record